The US dyslipidemia drugs market is witnessing steady growth due to the high prevalence of cardiovascular diseases, obesity, and diabetes, which increase the demand for effective lipid-lowering therapies. Advanced healthcare infrastructure, widespread cholesterol screening programs, and strong investment in pharmaceutical research are supporting the adoption of innovative dyslipidemia...